NasdaqGM:NTLABiotechs
Lonvo-z Phase 3 Allergy Congress Data Might Change The Case For Investing In Intellia Therapeutics (NTLA)
Intellia Therapeutics recently highlighted upcoming late-breaking phase 3 data for its experimental CRISPR-based therapy lonvo-z in hereditary angioedema, to be presented at the European Academy of Allergy & Clinical Immunology Congress 2026 in Istanbul from June 12–15.
This moment represents a key test of whether a one-time gene-editing approach can move closer to becoming a functional treatment option for a rare genetic disorder.
We will now explore how the upcoming lonvo-z phase 3 readout...